Key Highlights

  • Cash and cash equivalents were USD 444.0 million at September 30, 2026, which management believes funds operations into 2028.
  • The nine-month net loss was USD 172.4 million against USD 194.0 million a year earlier, and the accumulated Deficit stood at USD 995.0 million.
  • Management expects to complete the rolling new drug application within two weeks of the November 3, 2026 call, and the voucher sets a one to two month FDA review target.
  • The Phase 3 COMP005 and COMP006 trials showed differences of 3.6 and 3.8 points on the MADRS depression scale at week six.

Rolling Application Nears Completion With a Priority Voucher

Compass Pathways (NASDAQ:CMPS) filed its Quarterly Report and held its third quarter call on November 3, 2026. The biotechnology company is developing COMP360, a psilocybin treatment, for treatment-resistant depression, and has no approved products and no revenue. Management said it will complete its rolling new drug application within two weeks, and the FDA granted a National Priority Voucher in April 2026 that sets a one to two month review target. Management is aiming for a 2027 launch, and said cash on hand should carry the company through launch and into 2028. Its American depositary shares each represent one ordinary share. The FDA decision itself remains pending.

What the Phase 3 Data Show and What They Do Not

In the COMP005 trial, a single 25 mg dose beat placebo by 3.6 points on the MADRS scale at six weeks (p-value below 0.001). In COMP006, two 25 mg doses beat the 1 mg dose by 3.8 points. September 2026 open-label data from COMP005 Part C showed an average 13-point drop from baseline at week 52 for patients who received an additional dose, with 40% to 45% responders and about 30% remitters in the six weeks after dosing. Part C had no placebo arm, so those rates are not controlled comparisons. The company puts the United States treatment-resistant depression population at 4 million, with fewer than 3% treated with the only approved drug, SPRAVATO. Management also claims rapid onset within 24 hours and durability potentially out to 12 months, which are company characterizations rather than regulatory findings.

Funding Needs, Policy Exposure and Launch Execution

Operating losses will increase as the company completes the application and prepares to launch, and management says more funding will be needed over the longer term. Past funding came from share and ADS sales, an at-the-market program and a Hercules loan. An April 18, 2026 executive order seeks faster review of psychedelic therapies, yet the filing warns that policy, DEA licensing or FDA staffing changes could still delay or complicate progress. Company Market research says about 90% of interventional psychiatrists would prescribe COMP360 in the first year, a survey view rather than sales evidence. A Phase 2b/3 post-traumatic stress disorder trial is actively enrolling, and the company is exploring other label expansions.

Where Things Stand

It can plausibly reach an FDA decision soon, but approval is not assured. Compass Pathways (NASDAQ:CMPS) has two positive Phase 3 trials, a voucher that targets a review of one to two months, and USD 444.0 million of cash, which management says covers launch preparation into 2028. The weak points are that no product is yet approved, losses are rising into launch, and the long-term durability data come from an uncontrolled open-label part. Watch for the completed filing in mid-November, FDA communications, and any financing.